Development of new formulations of biologics: expectations, immunogenicity, and safety for subcutaneous trastuzumab (2018)
- Authors:
- USP affiliated authors: TIEZZI, DANIEL GUIMARÃES - FMRP ; ANDRADE, JURANDYR MOREIRA DE - FMRP
- Unidade: FMRP
- DOI: 10.1007/s40290-018-0247-5
- Subjects: NEOPLASIAS MAMÁRIAS; TERAPIA COMBINADA; QUIMIOTERAPIA
- Language: Inglês
- Imprenta:
- Source:
- Título: Pharmaceutical Medicine
- ISSN: 1178-2595
- Volume/Número/Paginação/Ano: v. 32, n. 5, p. 319-325, 2018
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: hybrid
- Licença: cc-by-nc
-
ABNT
PIMENTEL, Franklin Fernandes et al. Development of new formulations of biologics: expectations, immunogenicity, and safety for subcutaneous trastuzumab. Pharmaceutical Medicine, v. 32, n. 5, p. 319-325, 2018Tradução . . Disponível em: https://doi.org/10.1007/s40290-018-0247-5. Acesso em: 01 nov. 2024. -
APA
Pimentel, F. F., Morgan, G., Tiezzi, D. G., & Andrade, J. M. de. (2018). Development of new formulations of biologics: expectations, immunogenicity, and safety for subcutaneous trastuzumab. Pharmaceutical Medicine, 32( 5), 319-325. doi:10.1007/s40290-018-0247-5 -
NLM
Pimentel FF, Morgan G, Tiezzi DG, Andrade JM de. Development of new formulations of biologics: expectations, immunogenicity, and safety for subcutaneous trastuzumab [Internet]. Pharmaceutical Medicine. 2018 ; 32( 5): 319-325.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1007/s40290-018-0247-5 -
Vancouver
Pimentel FF, Morgan G, Tiezzi DG, Andrade JM de. Development of new formulations of biologics: expectations, immunogenicity, and safety for subcutaneous trastuzumab [Internet]. Pharmaceutical Medicine. 2018 ; 32( 5): 319-325.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1007/s40290-018-0247-5 - Volume of breast tissue excised during breast-conserving surgery in patients undergoing preoperative systemic therapy
- Expression of hypoxia-inducible factor 1-'alfa' and vascular endothelial growth factor-C in locally advanced breast cancer patients
- Mouse renal 4T1 cell engraftment as a model to study the influence of hypoxia in breast cancer progression
- Expression of aldehyde dehydrogenase after neoadjuvant chemotherapy is associated with expression of hypoxia-inducible factors 1 and 2 alpha and predicts prognosis in locally advanced breast cancer
- Recurrence and survival after neoadjuvant chemotherapy for locally advanced cervical cancer is dependent on the pathological response
- Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer
- HIF-1'alfa' and locally advanced breast cancer [Carta]
- Impact of surgical staging in locally advanced cervical cancer and subsequent chemotherapy
- Clinical criteria as predictive factors of response to primary hormone therapy in locally advanced breast cancer
- Treatment for low-risk gestational trophoblastic disease: comparison of single-agent methotrexate, dactnomycin and combination regimens
Informações sobre o DOI: 10.1007/s40290-018-0247-5 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
